Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.

BMS entered the radiopharma space via its $4.1 billion buyout of RayzeBio at the end of 2023. Unlike Novartis’ approved ...

A recent study from the Institute of Biomedicine at the University of Eastern Finland shows that the glucocorticoid receptor can both promote and ...

Acupuncture produced significantly greater reductions in nocturia episodes and IPSS scores in survivors of prostate cancer ...

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.

Jay Harris, who has anchored for SportsCenter for over 10 years has shared he has been diagnosed with prostate cancer and ...

An artificial intelligence-based tool identifies patients with high-risk, nonmetastatic prostate cancer (PCa) who would most likely benefit from treatment intensification, an investigator reported at ...

The immunotherapy CAN-2409 plus radiation therapy may fill an unmet treatment need for patients with localized intermediate- to high-risk prostate cancer.

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated ...

In recent years, there has been a headlong rush into the use of prostate-specific membrane antigen (PSMA)–targeted PET for the staging and restaging of men with prostate cancer (PC). To date, there ...